Etanercept

Generic Name: Etanercept

Brand Names: Enbrel, Eticovo, Benepali, Erelzi, Nepexto

Drug Type: Biotech

Chemical Formula: -

CAS Number: 185243-69-0

Unique Ingredient Identifier: OP401G7OJC

Background: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...

Indication: Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...

Associated Conditions: Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: -

Clinical Trials

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Etanercept
Drug: CHS-0214

First Posted Date: 2014-04-16

Last Posted Date: 2019-06-26

Lead Sponsor: Coherus Biosciences, Inc.

Target Recruit Count: 647

Registration Number: NCT02115750

Locations: 🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸
Dream Team Clinical Research, Anaheim, California, United States
🇺🇸
Arthritis Center of Nebraska, Lincoln, Nebraska, United States

and more 138 locations

Etanercept in Rheumatoid Arthritis and Vascular Inflammation

Phase 4

Terminated

Conditions: Rheumatoid Arthritis
Vascular Inflammation

Interventions: Drug: etanercept

First Posted Date: 2014-04-09

Last Posted Date: 2017-02-07

Lead Sponsor: Innovaderm Research Inc.

Target Recruit Count: 5

Registration Number: NCT02109289

Locations: 🇨🇦
Institut de rhumatologie de Montreal, Montreal, Quebec, Canada

TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial

Not Applicable

Withdrawn

Conditions: CRPS
Chronic Regional Pain Syndrome

Interventions: Drug: Placebo
Drug: Etanercept

First Posted Date: 2014-01-09

Last Posted Date: 2016-10-14

Lead Sponsor: Stanford University

Registration Number: NCT02031211

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Etanercept and Vascular Function in Psoriasis

Phase 2

Completed

Conditions: PSORIASIS

Interventions: Drug: Etanercept
Drug: Placebo

First Posted Date: 2013-11-21

Last Posted Date: 2014-12-19

Lead Sponsor: Emory University

Target Recruit Count: 24

Registration Number: NCT01989689

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: etanercept

First Posted Date: 2013-10-29

Last Posted Date: 2020-03-04

Lead Sponsor: University of Michigan

Target Recruit Count: 50

Registration Number: NCT01971346

Locations: 🇺🇸
University of Michigan Department of Dermatology, Ann Arbor, Michigan, United States

Safety and Efficacy Study of Etanercept for Aneurysmal Subarachnoid Hemorrhage

Phase 1

Withdrawn

Conditions: Subarachnoid Hemorrhage, Aneurysmal

Interventions: Drug: Etanercept

First Posted Date: 2013-05-31

Last Posted Date: 2020-11-02

Lead Sponsor: Unity Health Toronto

Registration Number: NCT01865630

Locations: 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada

Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

Completed

Conditions: Psoriasis

First Posted Date: 2013-03-18

Last Posted Date: 2017-08-11

Lead Sponsor: Jochen Schmitt.

Target Recruit Count: 1

Registration Number: NCT01812954

An Observational, Retrospective, Multicenter, National Study for the Monitoring of Subjects Who Participated in the LoadET Clinical Trial

Completed

Conditions: Ankylosing Spondylitis

First Posted Date: 2013-02-15

Last Posted Date: 2013-02-15

Lead Sponsor: Pfizer

Target Recruit Count: 85

Registration Number: NCT01793285

Locations: 🇪🇸
Pfizer Investigational Site, Valencia, Spain

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Phase 4

Active, not recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Etanercept
Drug: Infliximab
Drug: Adalimumab

First Posted Date: 2013-02-15

Last Posted Date: 2024-02-28

Lead Sponsor: Georgetown University

Target Recruit Count: 290

Registration Number: NCT01793519

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate

Phase 4

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Etanercept
Drug: Placebo

First Posted Date: 2013-02-04

Last Posted Date: 2016-01-06

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT01783015

Locations: 🇦🇺
RK Will Pty Ltd, Victoria Park, Western Australia, Australia
🇫🇷
Hopital Lapeyronie, Montpellier, France
🇷🇺
LLC "Alliance Biomedical - Russian Group", Izhevsk, Russian Federation

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy